Systemic therapeutic options in thymic malignancies

A glimmer of hope

Lisa A. Hammond-Thelin, Charles Thomas

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Progress in the systemic therapy of thymic malignancies has been hampered in the past by the rarity of this disease entity and the lack of a global collaborative effort in conducting phase II studies. Cisplatin-based therapy has been considered the standard of care, though data typically has been derived from a retrospective case-series approach. However, the arrival of novel cytotoxic agents and molecularly targeted agents into the clinic has helped provide the impetus for improved methodology in thymic malignancy research with an emphasis on more prospective phase II studies. This review discusses the results of traditional cytotoxic agents, novel cytotoxic agents, biologic therapy and the initial evaluation of molecularly targeted therapeutics, such as epidermal growth factor receptor inhibitors, for the treatment of thymic malignancies. In addition, potential novel targets such as VEGF, Bcl-2 and c-KIT are assessed.

Original languageEnglish (US)
Pages (from-to)191-205
Number of pages15
JournalReviews on Recent Clinical Trials
Volume2
Issue number3
DOIs
StatePublished - Sep 2007

Fingerprint

Cytotoxins
Neoplasms
Biological Therapy
Therapeutics
Standard of Care
Epidermal Growth Factor Receptor
Vascular Endothelial Growth Factor A
Cisplatin
Research

Keywords

  • Chemotherapy
  • Targeted therapy
  • Thymic carcinoma
  • Thymoma

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology

Cite this

Systemic therapeutic options in thymic malignancies : A glimmer of hope. / Hammond-Thelin, Lisa A.; Thomas, Charles.

In: Reviews on Recent Clinical Trials, Vol. 2, No. 3, 09.2007, p. 191-205.

Research output: Contribution to journalArticle

@article{d601eeda1bf44e0b8c4421ecbcb3058e,
title = "Systemic therapeutic options in thymic malignancies: A glimmer of hope",
abstract = "Progress in the systemic therapy of thymic malignancies has been hampered in the past by the rarity of this disease entity and the lack of a global collaborative effort in conducting phase II studies. Cisplatin-based therapy has been considered the standard of care, though data typically has been derived from a retrospective case-series approach. However, the arrival of novel cytotoxic agents and molecularly targeted agents into the clinic has helped provide the impetus for improved methodology in thymic malignancy research with an emphasis on more prospective phase II studies. This review discusses the results of traditional cytotoxic agents, novel cytotoxic agents, biologic therapy and the initial evaluation of molecularly targeted therapeutics, such as epidermal growth factor receptor inhibitors, for the treatment of thymic malignancies. In addition, potential novel targets such as VEGF, Bcl-2 and c-KIT are assessed.",
keywords = "Chemotherapy, Targeted therapy, Thymic carcinoma, Thymoma",
author = "Hammond-Thelin, {Lisa A.} and Charles Thomas",
year = "2007",
month = "9",
doi = "10.2174/157488707781662689",
language = "English (US)",
volume = "2",
pages = "191--205",
journal = "Reviews on Recent Clinical Trials",
issn = "1574-8871",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Systemic therapeutic options in thymic malignancies

T2 - A glimmer of hope

AU - Hammond-Thelin, Lisa A.

AU - Thomas, Charles

PY - 2007/9

Y1 - 2007/9

N2 - Progress in the systemic therapy of thymic malignancies has been hampered in the past by the rarity of this disease entity and the lack of a global collaborative effort in conducting phase II studies. Cisplatin-based therapy has been considered the standard of care, though data typically has been derived from a retrospective case-series approach. However, the arrival of novel cytotoxic agents and molecularly targeted agents into the clinic has helped provide the impetus for improved methodology in thymic malignancy research with an emphasis on more prospective phase II studies. This review discusses the results of traditional cytotoxic agents, novel cytotoxic agents, biologic therapy and the initial evaluation of molecularly targeted therapeutics, such as epidermal growth factor receptor inhibitors, for the treatment of thymic malignancies. In addition, potential novel targets such as VEGF, Bcl-2 and c-KIT are assessed.

AB - Progress in the systemic therapy of thymic malignancies has been hampered in the past by the rarity of this disease entity and the lack of a global collaborative effort in conducting phase II studies. Cisplatin-based therapy has been considered the standard of care, though data typically has been derived from a retrospective case-series approach. However, the arrival of novel cytotoxic agents and molecularly targeted agents into the clinic has helped provide the impetus for improved methodology in thymic malignancy research with an emphasis on more prospective phase II studies. This review discusses the results of traditional cytotoxic agents, novel cytotoxic agents, biologic therapy and the initial evaluation of molecularly targeted therapeutics, such as epidermal growth factor receptor inhibitors, for the treatment of thymic malignancies. In addition, potential novel targets such as VEGF, Bcl-2 and c-KIT are assessed.

KW - Chemotherapy

KW - Targeted therapy

KW - Thymic carcinoma

KW - Thymoma

UR - http://www.scopus.com/inward/record.url?scp=35048888892&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35048888892&partnerID=8YFLogxK

U2 - 10.2174/157488707781662689

DO - 10.2174/157488707781662689

M3 - Article

VL - 2

SP - 191

EP - 205

JO - Reviews on Recent Clinical Trials

JF - Reviews on Recent Clinical Trials

SN - 1574-8871

IS - 3

ER -